Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor

A technology of galectin and angiogenesis, applied in the field of using galectin protein inhibitors for treating, regulating or preventing ocular angiogenesis or fibrosis of subjects, compositions and kits, capable of solving Surgical recurrence and other issues

Inactive Publication Date: 2015-09-30
TUFTS UNIV +1
View PDF47 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is a risk of surgical recurrence

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
  • Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
  • Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0343] Preparation of galectin protein

[0344] It will be understood by those of ordinary skill in the art that the galectins of the present invention may be obtained from any available source. These include, but are not limited to, proteins isolated from natural sources, produced recombinantly or synthetically, for example, by solid phase procedures. According to the present invention, polynucleotide sequences, which encode galectin-3, galectin-7 or galectin-8, can be directed to the galectin of the present invention in a suitable host cell Recombinant DNA molecules for the expression of kinetochores are used. Cherayil et al., supra; Madsen et al., supra; and Hadri et al., supra; detailed galectin-7 and galectin-8 descriptions, respectively, of human galectin-1, human galectin- 3 clones. For the expression of biologically active human galectin-1, galectin-3, galectin-7 or galectin-8 encoded by the nucleotide sequence 3. Galectin-7, Galectin-8 or their functional equiva...

Embodiment 1

[0371] Example 1. For the synthesis of bis(3-deoxy-3-(3-fluorophenyl-1H-1,2,3-triazol-1-yl) - Materials and equipment for β-D-galactopyranosyl)sulfane

[0372] Bis(3-deoxy-3-(3-fluorophenyl-1H-1,2,3-triazol-1-yl)-β-D-galactopyranosyl)sulfane (TD139) was produced by Professional Post System (Profs) provided. Hakon Leffler and Ulf Nilsson (Lund University, Sweden), and prepared by administering the materials and methods of the invention described herein.

[0373] Melting points were recorded on a Kofler apparatus (Reichert) and were uncorrected. Proton NMR (1H) spectra were recorded using a Bruker DRX400 (400 MHz) or a Bruker ARX300 (300 MHz) spectrometer; the multiplicity was represented as singlet (s), peak (d), doublet (dd), triplet (t ), apparent triplet (ATD) or doublet apparent triplet (ATD) citations. Carbon NMR (13C) spectra were recorded using a Bruker DRX400 (100.6 MHz) spectrometer. Spectra were assigned using COZY, HMQC and DEPT experiments. All chemical shi...

Embodiment 2

[0378] Example 2. Phenyl 2-O-acetyl-4,6-O-benzylidene-1-thio-3-O-trifluoromethanesulfonyl- Synthesis of β-D-galactopyranoside (structural formula 2 in scheme 1)

[0379] Compound 1 (10.5 g, 29.2 mmol) was dissolved in dry pyridine (4.73 mL, 58.4 mmol) and dry CH 2 Cl 2 (132 ml). The reaction mixture was cooled with stirring to -20 °C (ice and NaCl bath, ratio 3:1). in N 2 Atmospheric conditions, slowly increase Tf 2 O (5.68 mL, 33.6 mmol) was added. The reaction mixture was monitored by TLC (heptane:EtOAc 1:1 and toluene:acetone 10:1). When the reaction was complete, AcCl (2.29 mL, 32.1 mmol) was added and stirred while the temperature was allowed to rise to room temperature. This mixture was monitored by TLC (heptane:EtOAc 1:1; and toluene:acetone 10:1). When the reaction is complete, use CH 2 Cl 2 Quenched with 5% HCl, NaHCO 3 (saturated) and NaCl (saturated) for washing. Among them, the organic layer uses MgSO 4 It was dried, filtered and concentrated under ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods and kits using a pharmaceutical composition for use in inhibiting ocular angiogenesis or fibrosis are provided herein, such that composition includes a pharmaceutically suitable carrier or diluent and an amount of the inhibitor composition effective to inhibit the angiogenesis or the fibrosis by inhibiting expression and / or activity of a galectin protein or a portion thereof.

Description

[0001] related application [0002] This application claims U.S. Provisional Application Serial No. 61 / 726,998, filed November 15, 2012, and entitled "Use of a Galectin Protein Inhibitor for the Treatment, Modulation, or Prevention of Ocular Angiogenesis or Fibrosis in a Subject" The inventors of the above provisional application are N. Panjivani, Chen Weisheng, H. Leffler and U. Nielsen. This application has been incorporated by reference in its entirety. technical field [0003] The present invention relates to methods and kits for the use of pharmaceutical compositions in the application of inhibiting ocular angiogenesis or ocular fibrosis in a subject. [0004] governmental support [0005] This invention was made with government support under grant number EY007088 from the National Institute of Health. This government agency has certain rights in this invention. Background technique [0006] Disorders associated with ocular angiogenesis, such as choroidogenesis vasc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61K31/732A61K31/70A61P27/02
CPCA61K31/70A61K38/17A61K45/06A61K31/7028A61K31/7056A61P27/02Y02A50/30A61K2300/00A61J1/00
Inventor N·潘吉瓦尼陈玮笙H·莱弗勒U·尼尔森
Owner TUFTS UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com